FLT4 and breast carcinoma: Thus, while lymphatic-targeted anti-VEGFR3 therapy alone shows no effect on tumor growth, it can synergize with docetaxel to potentially enhance chemosensitivity and significantly reduce tumor growth in 4T1 mammary carcinoma.